AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7666123 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam (2 g ampicillin plus 1 g sulbactam intravenously every 6 h)
Number of subjects: 53
Study 7666123 — intervention group
Group type: COMPARATOR
Intervention: cefotaxime (2 g intravenously every 6 h)
Number of subjects: 53
Study 2533973 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 102-126 (WY 47987) bolus injections at 1, 2, and 3 micrograms/kg i.v.
Number of subjects: 11
Study 2533973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 160068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (2 puffs of 0.02 mg each)
Number of subjects: 6
Study 160068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (2 puffs of 0.2 mg each)
Number of subjects: 6
Study 160068 — intervention group
Group type: COMPARATOR
Intervention: Isoprenaline (inhaled at the end of the experiment)
Number of subjects: 6
Study 30496870 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A vaccine (HA-L)
Number of subjects: 9000
Study 30496870 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (HA-I)
Number of subjects: 9000
Study 30496870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HA-L and HA-I vaccines
Number of subjects: 9000
Study 27933450 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth with pedometer
Number of subjects: 356
Study 27933450 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise program using brochure
Number of subjects: 356
Study 24862305 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training and heavy strength training (ES)
Number of subjects: 16
Study 24862305 — intervention group
Group type: COMPARATOR
Intervention: Endurance training only (E)
Number of subjects: 16
Study 23589562 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (activated 1 month after device implantation)
Number of subjects: 322
Study 23589562 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (activated 6 months after device implantation)
Number of subjects: 322
Study 23589562 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (both groups)
Number of subjects: 322
Study 16886724 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (2.5 +/- 1 mg/day)
Number of subjects: 9
Study 15181130 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET
Number of subjects: 21
Study 15181130 — intervention group
Group type: COMPARATOR
Intervention: Clinical and US examinations
Number of subjects: 21
Study 10639180 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta oscillations observed in left hippocampus
Number of subjects: 0
Study 10639180 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta oscillations observed in right hippocampus
Number of subjects: 0
Study 10639180 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus-locked theta duration
Number of subjects: 0
Study 10639180 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal theta involvement
Number of subjects: 0
Study 10639180 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory phase reset of theta
Number of subjects: 0
Study 8841148 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg)
Number of subjects: 12
Study 8841148 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (200 mg)
Number of subjects: 12
Study 1462609 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofragmentable Anastomosis Ring (Valtrac‐BAR)
Number of subjects: 170
Study 1462609 — intervention group
Group type: COMPARATOR
Intervention: Manual suture (3‐0 Dexon, two layers)
Number of subjects: 170
Study 1462609 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BAR and manual suture)
Number of subjects: 170
Study 6397578 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy 3000 rad/10 fractions (treatment 1)
Number of subjects: 116
Study 6397578 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus metronidazole 6 gm/m2 (treatment 2)
Number of subjects: 116
Study 31969072 — intervention group
Group type: EXPERIMENTAL
Intervention: smRSq
Number of subjects: 0
Study 31969072 — intervention group
Group type: EXPERIMENTAL
Intervention: mRS
Number of subjects: 0
Study 31405867 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline 100 mg i.v.
Number of subjects: 0
Study 31405867 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline 300 mg i.v.
Number of subjects: 0
Study 31405867 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 0
Study 31405867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 0
Study 29126170 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith-integrated program (FI)
Number of subjects: 465
Study 29126170 — intervention group
Group type: COMPARATOR
Intervention: Self-guided control program (C)
Number of subjects: 465
Study 29126170 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-faith integrated program (NFI)
Number of subjects: 465
Study 25619634 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice (Control)
Number of subjects: 334
Study 25619634 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (greater patient involvement with reminders)
Number of subjects: 334
Study 25619634 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (greater patient involvement with reminders plus regular phone calls and meetings)
Number of subjects: 334
Study 25619634 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly drug administration
Number of subjects: 334
Study 25619634 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly drug administration
Number of subjects: 334
Study 23080361 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measure of attitudes toward sexual partner concurrency
Number of subjects: 370
Study 22170276 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (STN-DBS)
Number of subjects: 119
Study 22170276 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 119
Study 19368768 — intervention group
Group type: EXPERIMENTAL
Intervention: Split H7N1 virus vaccine with 12 microg haemagglutinin
Number of subjects: 60
Study 19368768 — intervention group
Group type: EXPERIMENTAL
Intervention: Split H7N1 virus vaccine with 24 microg haemagglutinin
Number of subjects: 60
Study 19368768 — intervention group
Group type: EXPERIMENTAL
Intervention: Split H7N1 virus vaccine with 12 microg haemagglutinin and 300 microg aluminium hydroxide adjuvant
Number of subjects: 60
Study 19368768 — intervention group
Group type: EXPERIMENTAL
Intervention: Split H7N1 virus vaccine with 24 microg haemagglutinin and 600 microg aluminium hydroxide adjuvant
Number of subjects: 60
Study 16448520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily for 24 weeks
Number of subjects: 690
Study 16448520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg once daily for 24 weeks
Number of subjects: 690
Study 12633795 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin ER/lovastatin 1,000/40 mg
Number of subjects: 315
Study 12633795 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 315
Study 12633795 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 315
Study 12633795 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin ER/lovastatin
Number of subjects: 315
Study 12633795 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg and Simvastatin 20 mg
Number of subjects: 315
Study 10835443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol in fruit juice (1.5 g/kg)
Number of subjects: 12
Study 10835443 — intervention group
Group type: COMPARATOR
Intervention: Fruit juice alone (control)
Number of subjects: 12
Study 8671103 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Interview Satisfaction Scale (MISS)
Number of subjects: 198
Study 8671103 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation Satisfaction Questionnaire (CSQ)
Number of subjects: 198
Study 8671103 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between overall scales (MISS and CSQ)
Number of subjects: 198
Study 8671103 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability of MISS
Number of subjects: 198
Study 8671103 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability of CSQ
Number of subjects: 198
Study 8671103 — intervention group
Group type: COMPARATOR
Intervention: Patient satisfaction scores based on completion location
Number of subjects: 198
Study 1532187 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical, related, and unrelated primes presented for 60, 45, or 30 ms
Number of subjects: 0
Study 1532187 — intervention group
Group type: EXPERIMENTAL
Intervention: Random letter string (in place of identical prime) with prime durations of 39, 30, or 21 ms
Number of subjects: 0
Study 3923748 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural blockade for 24 h
Number of subjects: 16
Study 3923748 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extradural blockade)
Number of subjects: 16
Study 30702055 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and behavioral activation psychotherapy
Number of subjects: 150
Study 29265546 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy
Number of subjects: 76
Study 27473384 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Number of subjects: 81
Study 27473384 — intervention group
Group type: COMPARATOR
Intervention: Epogen
Number of subjects: 81
Study 24380989 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (125 mg in normal saline 50 cc)
Number of subjects: 114
Study 24380989 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline
Number of subjects: 114
Study 22359078 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitex agnus castus (40 drops, administered for 6 days before menses for 6 consecutive cycles)
Number of subjects: 128
Study 22359078 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo administered for 6 days before menses for 6 consecutive cycles)
Number of subjects: 128
Study 20664534 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 11
Study 17629361 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 15
Study 17629361 — intervention group
Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (23vPS)
Number of subjects: 15
Study 15897479 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate (CHO)/low fat (LF) diet (60% CHO, 20% fat)
Number of subjects: 21
Study 15897479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate (LC)/high fat (HF) diet (40% CHO, 40% fat)
Number of subjects: 21
Study 15897479 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall changes in insulin sensitivity (Si)
Number of subjects: 21
Study 12451200 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 24
Study 12451200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10509204 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser (0.5 to 1.5 joules per pulse, 5 and 25 Hertz, total energy 1 to 2 K joules)
Number of subjects: 55
Study 10509204 — intervention group
Group type: COMPARATOR
Intervention: Conventionally instrumented group
Number of subjects: 55
Study 8545140 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong opioid agonists
Number of subjects: 0
Study 8545140 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of paracetamol and codeine
Number of subjects: 0
Study 8545140 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment suggestions
Number of subjects: 0
Study 8545140 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' experience
Number of subjects: 0
Study 1835005 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone, 5 mg three times a day from day 19 to 26
Number of subjects: 24
Study 1835005 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol, 200 mg daily
Number of subjects: 24
Study 1835005 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone
Number of subjects: 24
Study 1835005 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 24
Study 7129917 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoureteral manipulation
Number of subjects: 30
Study 7129917 — intervention group
Group type: COMPARATOR
Intervention: Anti-inflammatory drugs and analgesics
Number of subjects: 30
Study 30887768 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic radical hysterectomy (TLRH) with no-look no-touch technique
Number of subjects: 163
Study 30887768 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (ARH)
Number of subjects: 163
Study 30887768 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic radical hysterectomy (TLRH)
Number of subjects: 163
Study 27671975 — intervention group
Group type: EXPERIMENTAL
Intervention: Action planning condition
Number of subjects: 243
Study 27671975 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory planning condition
Number of subjects: 243
Study 27671975 — intervention group
Group type: COMPARATOR
Intervention: Standard information control condition
Number of subjects: 243
Study 26021958 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (12 sessions)
Number of subjects: 30
Study 26021958 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (12 sessions)
Number of subjects: 30
Study 23522993 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-hydrogel contact lenses worn full time for six months
Number of subjects: 60
Study 21536455 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Healthy Women intervention
Number of subjects: 362
Study 21536455 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 362
Study 19527160 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard briefing
Number of subjects: 0
Study 19527160 — intervention group
Group type: COMPARATOR
Intervention: Standard briefing plus mnemonic
Number of subjects: 0
Study 17619851 — intervention group
Group type: EXPERIMENTAL
Intervention: TURIS (Olympus, SurgMasterSystem)
Number of subjects: 128
Study 17619851 — intervention group
Group type: COMPARATOR
Intervention: Conventional TUR
Number of subjects: 128
Study 17619851 — intervention group
Group type: EXPERIMENTAL
Intervention: TURIS
Number of subjects: 128
Study 13680073 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 14
Study 13680073 — intervention group
Group type: COMPARATOR
Intervention: Sham session (placebo)
Number of subjects: 14
Study 11216318 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-example condition (decreasing numbers)
Number of subjects: 0
Study 11216318 — intervention group
Group type: COMPARATOR
Intervention: Original version (increasing numbers)
Number of subjects: 0
Study 9046253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed Glaucoma Valve implant
Number of subjects: 21
Study 7639371 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 0.2 mg/kg loading dose followed by 0.5 mg.kg-1.h-1 infusion
Number of subjects: 98
Study 7639371 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 0.4 mg/kg loading dose followed by 1 mg.kg-1.h-1 infusion
Number of subjects: 98
Study 7639371 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 0.5 mg/kg loading dose followed by 2 mg.kg-1.h-1 infusion
Number of subjects: 98
Study 7639371 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 0.7 mg/kg loading dose followed by 4 mg.kg-1.h-1 infusion
Number of subjects: 98
Study 3064648 — intervention group
Group type: EXPERIMENTAL
Intervention: red rubber tubes (HPC)
Number of subjects: 500
Study 3064648 — intervention group
Group type: EXPERIMENTAL
Intervention: latex-spiral tubes (HPC)
Number of subjects: 500
Study 3064648 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC tubes (LPC)
Number of subjects: 500
Study 3064648 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC tubes with rediffusion system (LPC)
Number of subjects: 500
Study 3064648 — intervention group
Group type: COMPARATOR
Intervention: face mask
Number of subjects: 500
Study 30351388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with dairy foods (MedDairy)
Number of subjects: 41
Study 30351388 — intervention group
Group type: COMPARATOR
Intervention: Low-fat (LF) control diet
Number of subjects: 41
Study 27726525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with weekly face‐to‐face meetings to reduce BPA exposures, provided with BPA‐free cosmetics, hygiene products, glass containers, and self-monitoring tools
Number of subjects: 24
Study 27726525 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 26185417 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg/kg every other week (EOW)
Number of subjects: 44
Study 26185417 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg weekly
Number of subjects: 44
Study 26185417 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg/kg EOW
Number of subjects: 44
Study 26185417 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg weekly
Number of subjects: 44
Study 23394779 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa stimulation protocol (triptorelin on alternate days, recombinant FSH, and recombinant hCG microdose)
Number of subjects: 96
Study 23394779 — intervention group
Group type: COMPARATOR
Intervention: GnRHant protocol (daily dose of recombinant FSH, cetrorelix, and rhCG microdose)
Number of subjects: 96
Study 20192725 — intervention group
Group type: EXPERIMENTAL
Intervention: BID (400 mg lopinavir and 100 mg ritonavir twice daily)
Number of subjects: 321
Study 20192725 — intervention group
Group type: COMPARATOR
Intervention: QD (800 mg lopinavir and 200 mg ritonavir once daily)
Number of subjects: 321
Study 18336483 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1.0 microg x kg(‐1)
Number of subjects: 60
Study 18336483 — intervention group
Group type: COMPARATOR
Intervention: saline (group S)
Number of subjects: 60
Study 18336483 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.5 microg x kg(‐1) (group R 0.5)
Number of subjects: 60
Study 16526127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (etidronate, alendronate, risedronate, clodronate)
Number of subjects: 18667
Study 16526127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18667
Study 12934762 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (group I)
Number of subjects: 41
Study 12934762 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilation (group II)
Number of subjects: 41
Study 10381291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day for 6 weeks
Number of subjects: 7
Study 8963837 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LCE)
Number of subjects: 58
Study 8963837 — intervention group
Group type: COMPARATOR
Intervention: Conventional cholecystectomy (CCE)
Number of subjects: 58
Study 1986973 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingotomy without tubal suturing
Number of subjects: 34
Study 1986973 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingotomy with tubal suturing
Number of subjects: 34
Study 1986973 — intervention group
Group type: COMPARATOR
Intervention: Salpingectomy (historical control)
Number of subjects: 34
Study 1986973 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingotomy with or without tubal suturing
Number of subjects: 34
Study 6342335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily plus propantheline 45 mg daily (group A)
Number of subjects: 58
Study 6342335 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1 g daily plus placebo (group B)
Number of subjects: 58
Study 6342335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg daily
Number of subjects: 58
Study 6342335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime plus propantheline 45 mg daily
Number of subjects: 58
Study 6342335 — intervention group
Group type: EXPERIMENTAL
Intervention: Propantheline 90 mg daily
Number of subjects: 58
Study 2412045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg i.v.)
Number of subjects: 10
Study 28933977 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention program
Number of subjects: 30
Study 28933977 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 26462903 — intervention group
Group type: EXPERIMENTAL
Intervention: Humeral intraosseous (HIO) epinephrine administration
Number of subjects: 32
Study 26462903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial intraosseous (TIO) epinephrine administration
Number of subjects: 32
Study 26462903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) epinephrine administration
Number of subjects: 32
Study 26462903 — intervention group
Group type: COMPARATOR
Intervention: Control group (i.v. with defibrillation but no epinephrine)
Number of subjects: 32
Study 24655695 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella 2.5
Number of subjects: 448
Study 24655695 — intervention group
Group type: COMPARATOR
Intervention: Intra-Aortic Balloon Pump (IABP)
Number of subjects: 448
Study 22498664 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening group (n = 17)
Number of subjects: 50
Study 22498664 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching group (n = 17)
Number of subjects: 50
Study 22498664 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 50
Study 22498664 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening group vs Stretching group
Number of subjects: 50
Study 20859144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation
Number of subjects: 160
Study 20859144 — intervention group
Group type: COMPARATOR
Intervention: Hydrothermablation
Number of subjects: 160
Study 18492754 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily PTH 1-34
Number of subjects: 14
Study 18492754 — intervention group
Group type: COMPARATOR
Intervention: Once-daily PTH 1-34
Number of subjects: 14